ArcticZymes Technologies
- Company typePublic
- Founded1995
- HeadquartersTromsø, Norway
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
ArcticZymes Technologies firmographics
Firmographics- Name
- ArcticZymes Technologies
- Legal name
- ArcticZymes Technologies ASA
- Website
- https://arcticzymes.com
- Company type
- Public
- Founded year
- 1995
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
ArcticZymes Technologies industry classification
Industry- Product category
- Specialty Enzymes for Biomanufacturing and Molecular Diagnostics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Medicinal Chemicals & Botanical Products (2833)
- akta.pro primary industry
- Protein Processing Enzymes (Meat/Seafood/Plant) (AFAJAIAF)
- akta.pro secondary industry
- Enzyme Premixes (Phytase, NSP Enzymes, Proteases) (AFADAGAF)
Keywords
Where ArcticZymes Technologies is headquartered
LocationHeadquarters
- HQ city
- Tromsø
- HQ country
- Norway
- HQ region
- Europe
Offices1 record
Markets served
ArcticZymes Technologies business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure
Revenue model
- Enzyme Product Sales: ArcticZymes generates revenue through the sale of specialized enzymes and kits for biomanufacturing, molecular diagnostics, and molecular research applications. Products include nucleases (SAN HQ, M-SAN HQ, HL-SAN, dsDNase), polymerase enzymes, UNG enzymes, and associated ELISA detection kits. Revenue is generated through both direct sales and distribution partnerships. Full-year 2025 revenue totaled NOK 118.2 million, with Q4 2025 at NOK 34.7 million representing 31% year-on-year growth.
- GMP-Grade Products: Sale of GMP-grade enzymes for biopharmaceutical manufacturing. GMP-grade products command premium pricing and include comprehensive regulatory support documentation. The company reported 106% year-on-year growth in GMP-grade product sales in Q4 2025, indicating strong momentum in this segment.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | M-SAN HQ bioprocessing grade - various pack sizes |
| Unit Pricing | Pay-as-you-go | SAN HQ high salt nuclease - research and GMP grades |
| Unit Pricing | Pay-as-you-go | M-SAN HQ ELISA Kit - 96 well plate format |
| Unit Pricing | Pay-as-you-go | SAN HQ ELISA SensoPlus - sensitive detection kit |
| Unit Pricing | Pay-as-you-go | dsDNase and HL-dsDNase - DNA-specific nucleases |
| Unit Pricing | Pay-as-you-go | Cod UNG - heat-labile uracil-DNA glycosylase |
| Unit Pricing | Pay-as-you-go | AZtaq DNA Polymerase |
| Unit Pricing | Pay-as-you-go | Heat&Run gDNA Removal Kit |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels6 records
ArcticZymes Technologies product offering
Product offeringCore offering
ArcticZymes Technologies develops, manufactures, and commercializes specialty enzymes and kits derived from cold-adapted Arctic marine organisms for biomanufacturing, molecular diagnostics, and molecular research applications. Its core offerings include Salt Active Nucleases (SAN HQ and M-SAN HQ) for residual DNA removal in viral vector and gene therapy manufacturing, heat-labile nucleases and polymerases for molecular diagnostics, and GMP-grade enzyme variants with regulatory documentation for therapeutic production.
Product overview
ArcticZymes Technologies offers a portfolio of specialized enzymatic products organized into two main segments: Biomanufacturing and Molecular Diagnostics. The Biomanufacturing segment centers on Salt Active Nucleases (SAN HQ and M-SAN HQ) and their GMP-grade variants, designed for viral vector purification, gene therapy, and vaccine manufacturing. These are complemented by ELISA detection kits (SAN HQ ELISA SensoPlus, M-SAN HQ ELISA Kit) for residual enzyme quantification. The Molecular Diagnostics segment includes HL-SAN for metagenomic workflows, dsDNase and HL-dsDNase for DNA-specific applications, HL-ExoI for exonuclease reactions, Cod UNG for PCR contamination control, and a suite of isothermal polymerases (IsoPol SD+, IsoPol BST+) for LAMP and other isothermal amplification methods. Supporting products include AZtaq DNA Polymerase, AZscript Reverse Transcriptase, T4 DNA Ligase, R2D Ligase, rSAP, AZ Proteinase, T7 RNA Polymerase, and specialized kits such as the Heat&Run gDNA Removal Kit and PCR Decontamination Kit. The products are characterized by their cold-adapted origins, unique salt-tolerance properties, and heat-labile inactivation capabilities.
Differentiator
Problem solved
Functional benefit
Products and services
- SAN HQ (Salt Active Nuclease High Quality)
- M-SAN HQ (Medium Salt Active Nuclease High Quality)
- SAN HQ GMP (Good Manufacturing Practice Grade)
- M-SAN HQ GMP
- SAN HQ ELISA SensoPlus
- M-SAN HQ ELISA Kit
- HL-SAN (Heat-Labile Salt Active Nuclease)
- dsDNase
- HL-dsDNase
- HL-ExoI (Heat-Labile Exonuclease I)
- Heat&Run gDNA Removal Kit
- PCR Decontamination Kit
- Cod UNG (Codon Uracil-DNA Glycosylase)
- IsoPol SD+ (Isothermal Polymerase Low Temperature)
- IsoPol BST+ (Isothermal Polymerase High Temperature)
- AZtaq DNA Polymerase
- AZscript Reverse Transcriptase
- T4 DNA Ligase
- R2D Ligase (RNA to DNA Ligase)
- rSAP (Shrimp Alkaline Phosphatase)
- AZ Proteinase
- T7 RNA Polymerase
Quantifiable outcome
- Up to 2-fold reduction in residual DNA compared to standard nucleases
- +3 more outcomes
Companies that use ArcticZymes Technologies
Customer profileNamed customers1 record
Segments3 records
Ideal customer profiles3 records
ArcticZymes Technologies technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
ArcticZymes Technologies partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- BrenntagkeyExclusive European distribution agreement for Salt Active Nucleases product line. The partnership was announced in late 2025 and leverages Brenntag's established distribution network to enhance market reach in the biopharmaceutical sector. The agreement was formalized during the CPHI fair in Frankfurt and supports ArcticZymes' strategy to expand commercialization across European markets for biomanufacturing applications including gene therapy and vaccine manufacturing.
Scale indicators7 records
Recent moves2 records
Expansion highlights6 records
ArcticZymes Technologies competitors and assessment
Company assessmentDirect peers
- New England Biolabs: Privately held specialty enzyme manufacturer with the broadest molecular biology enzyme portfolio globally. Directly competes with ArcticZymes in nucleases, polymerases, ligases, and other specialty enzymes for research and biomanufacturing applications, including some overlap in GMP-grade offerings.
- Promega Corporation: Privately held specialty reagent and enzyme manufacturer with similar focus on molecular biology tools, sample preparation, and clinical research reagents. Comparable in scale and product philosophy, with overlap in nucleases, polymerases, and molecular diagnostics enzymes.
Broad incumbents
- Thermo Fisher Scientific: Diversified life sciences leader offering enzymes through its Invitrogen and Thermo Scientific brands. Overlaps with ArcticZymes in PCR/qPCR reagents, polymerases, and bioprocessing enzymes, but as part of a much broader portfolio serving every major life sciences customer.
- Merck KGaA (MilliporeSigma): Life sciences arm of Merck KGaA offering an extensive enzyme catalog under Sigma-Aldrich and MilliporeSigma. Directly competes with ArcticZymes in bioprocessing nucleases, residual DNA removal, and molecular biology enzymes, with much deeper global sales coverage.
- QIAGEN: Provider of sample preparation and molecular diagnostics solutions, including enzymes and kits for nucleic acid workflows. Overlaps with ArcticZymes in DNA removal and sample prep enzymes used in both research and clinical diagnostics.
- Bio-Techne: Life sciences reagent company offering proteins, enzymes, and diagnostic reagents. Comparable in targeting molecular biology and diagnostics customers with specialty reagent products, though broader in scope including proteins and antibodies.
- Sartorius: Bioprocessing equipment and consumables supplier serving the same gene therapy, vaccine, and biologics manufacturing customers as ArcticZymes. Overlaps in biomanufacturing workflows (downstream processing), with enzyme reagents being a complementary rather than directly competing offering.
- Cytiva (Danaher): Bioprocessing solutions provider owned by Danaher serving viral vector, vaccine, and biologics manufacturers. Targets the same biopharma manufacturing customers as ArcticZymes with broader workflow solutions including purification and filtration.
Emerging players
- Codexis: Specialty enzyme developer using directed evolution to engineer enzymes for biopharmaceutical manufacturing and molecular diagnostics. Comparable focus on engineered enzyme platforms for therapeutic manufacturing customers, though broader into small-molecule biocatalysis.
Others
- Biophorum: Industry collaboration group setting standards in biopharmaceutical manufacturing. Not a direct competitor but a key ecosystem participant where ArcticZymes engages with biomanufacturing customers and influences industry adoption of nuclease technologies.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
ArcticZymes Technologies social profiles
Digital presenceArcticZymes Technologies compliance and trust
Trust signalCompliance3 records
ArcticZymes Technologies financial estimates
Financial estimateRevenue estimate
Valuation estimate
ArcticZymes Technologies leadership team
Management profileNumber of profiles
Profiles1 record
ArcticZymes Technologies funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ArcticZymes Technologies M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ArcticZymes Technologies
What does ArcticZymes Technologies do?
ArcticZymes Technologies develops, manufactures, and commercializes specialty enzymes and kits derived from cold-adapted Arctic marine organisms for biomanufacturing, molecular diagnostics, and molecular research applications. Its core offerings include Salt Active Nucleases (SAN HQ and M-SAN HQ) for residual DNA removal in viral vector and gene therapy manufacturing, heat-labile nucleases and polymerases for molecular diagnostics, and GMP-grade enzyme variants with regulatory documentation for therapeutic production.
Is ArcticZymes Technologies a public or private company?
ArcticZymes Technologies is a public company. It is classified as public and is currently operating.
When was ArcticZymes Technologies founded?
ArcticZymes Technologies was founded in 1995. It employs 11 to 50 people.
Where is ArcticZymes Technologies based?
ArcticZymes Technologies is headquartered in Tromsø, Norway, in the Europe region.
How does ArcticZymes Technologies make money?
Two revenue lines are on record. Enzyme Product Sales are the primary driver. The others are GMP-Grade Products.
Who are ArcticZymes Technologies's main competitors?
Direct peers on record are New England Biolabs and Promega Corporation. Broad incumbents are Thermo Fisher Scientific, Merck KGaA (MilliporeSigma), QIAGEN, Bio-Techne, Sartorius and Cytiva (Danaher). Codexis is listed as an emerging player. Biophorum is listed as an others.
Does ArcticZymes Technologies have an API?
No public API is recorded for ArcticZymes Technologies.
What industry is ArcticZymes Technologies in?
ArcticZymes Technologies's product category is Specialty Enzymes for Biomanufacturing and Molecular Diagnostics. Its primary akta.pro industry code is AFAJAIAF, Protein Processing Enzymes (Meat/Seafood/Plant), with a secondary code of AFADAGAF, Enzyme Premixes (Phytase, NSP Enzymes, Proteases). Its NAICS code is 325414 and its SIC code is 2836.